{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:37:52Z","timestamp":1791041872951,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["26mk0121322h0102"],"award-info":[{"award-number":["26mk0121322h0102"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K06217"],"award-info":[{"award-number":["23K06217"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.dmd.2026.100283","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:37:02Z","timestamp":1774658222000},"page":"100283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Baseline variations in in vivo cytochrome P450 3A-dependent phenotypes evaluated using concentrations of endogenous or deuterium-labeled cortisol and their 6\u03b2-hydroxylated metabolites in 103 cynomolgus monkeys and 20 humanized-liver mice transplanted with hepatocytes"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1359-8828","authenticated-orcid":false,"given":"Shotaro","family":"Uehara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2508-4031","authenticated-orcid":false,"given":"Makiko","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Shimoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-2454","authenticated-orcid":false,"given":"Hiroshi","family":"Suemizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1068-4261","authenticated-orcid":false,"given":"Hiroshi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dmd.2026.100283_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cpt.3625","article-title":"ICH M12 drug interaction studies: summary of the efforts to achieve global convergence","volume":"118","author":"Reynolds","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2026.100283_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2025.101512","article-title":"Future directions in drug-drug interaction evaluations: industry perspective on the ICH M12 guidance","volume":"66","author":"Umehara","year":"2026","journal-title":"Drug Metab Pharmacokinet"},{"issue":"1","key":"10.1016\/j.dmd.2026.100283_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.dmpk.2019.11.009","article-title":"Development of a new Japanese guideline on drug interaction for drug development and appropriate provision of information","volume":"35","author":"Ishiguro","year":"2020","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.dmd.2026.100283_bib4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1210\/jcem-52-3-381","article-title":"6 beta-Hydroxycortisol: a noninvasive indicator of enzyme induction","volume":"52","author":"Saenger","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.dmd.2026.100283_bib5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.1981.tb01186.x","article-title":"Assessment of urinary 6 beta-hydroxycortisol as an in vivo index of mixed-function oxygenase activity","volume":"12","author":"Park","year":"1981","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.dmd.2026.100283_bib6","first-page":"441","article-title":"A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans","volume":"29","author":"Bienvenu","year":"1991","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100283_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2125.1989.tb03516.x","article-title":"The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction","volume":"28","author":"Ged","year":"1989","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100283_bib8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/03602532.2015.1011658","article-title":"Regioselective hydroxylation of steroid hormones by human cytochromes P450","volume":"47","author":"Niwa","year":"2015","journal-title":"Drug Metab Rev"},{"issue":"1","key":"10.1016\/j.dmd.2026.100283_bib9","doi-asserted-by":"crossref","first-page":"332","DOI":"10.18433\/jpps30558","article-title":"Comparison of steroid hormone hydroxylations by and docking to human cytochromes P450 3A4 and 3A5. 3","volume":"22","author":"Niwa","year":"2019","journal-title":"J Pharm Pharm Sci"},{"issue":"5","key":"10.1016\/j.dmd.2026.100283_bib10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s002280050390","article-title":"Changes in urinary 6beta-hydroxycortisol\/cortisol ratio after birth in human neonates","volume":"53","author":"Nakamura","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100283_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2125.1999.00857.x","article-title":"Comparison of urinary 6beta-hydroxycortisol\/cortisol ratio between neonates and their mothers","volume":"47","author":"Nakamura","year":"1999","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100283_bib12","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/bcp.15987","article-title":"Plasma 6\u03b2-hydroxycortisol to cortisol ratio as a less invasive cytochrome P450 3A phenotyping method","volume":"90","author":"Hirano","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.dmd.2026.100283_bib13","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1124\/dmd.124.001876","article-title":"Quantitative prediction of drug-drug interactions caused by CYP3A induction using endogenous biomarker 4beta-hydroxycholesterol","volume":"52","author":"Takubo","year":"2024","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100283_bib14","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3389\/fgene.2020.00944","article-title":"Inherited and acquired determinants of hepatic CYP3A activity in humans","volume":"11","author":"Matthaei","year":"2020","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.dmd.2026.100283_bib15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.dmd.2026.100283_bib16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.psyneuen.2018.11.035","article-title":"Associations between symptoms of depression and anxiety and cortisol responses to and recovery from acute stress","volume":"102","author":"Fiksdal","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.dmd.2026.100283_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2025.107617","article-title":"Chronic corticosterone impaired effortful motivation and risky decision-making in mice","volume":"181","author":"Noback","year":"2025","journal-title":"Psychoneuroendocrinology"},{"issue":"3","key":"10.1016\/j.dmd.2026.100283_bib18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/jcm10030517","article-title":"Salivary biomarkers of stress, anxiety and depression","volume":"10","author":"Chojnowska","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.dmd.2026.100283_bib19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/00498254.2017.1288945","article-title":"R-warfarin clearances from plasma associated with polymorphic cytochrome P450 2C19 and simulated by individual physiologically based pharmacokinetic models for 11 cynomolgus monkeys","volume":"48","author":"Utoh","year":"2018","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmd.2026.100283_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100410","article-title":"An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both male and female animals","volume":"42","author":"Uehara","year":"2022","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmd.2026.100283_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbrc.2023.04.054","article-title":"HepaSH cells: Experimental human hepatocytes with lesser inter-individual variation and more sustainable availability than primary human hepatocytes","volume":"663","author":"Uehara","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.dmd.2026.100283_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2023.100504","article-title":"Roles of human cytochrome P450 3A4\/5 in dexamethasone 6\u03b2-hydroxylation mediated by liver microsomes and humanized liver in chimeric mice metabolically suppressed with azamulin","volume":"50","author":"Uehara","year":"2023","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmd.2026.100283_bib23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1124\/dmd.114.057224","article-title":"4\u03b2-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys","volume":"42","author":"Li","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100283_bib24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/bdd.2173","article-title":"A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys","volume":"40","author":"Tahara","year":"2019","journal-title":"Biopharm Drug Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2026.100283_bib25","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":"Genetic contribution to variable human CYP3A-mediated metabolism","volume":"54","author":"Lamba","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.dmd.2026.100283_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.dmd.2026.100283_bib27","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1007\/s00204-025-04135-8","article-title":"Evaluating CYP enzyme induction by cigarette smoking: a new in vitro approach using primary human hepatocytes","volume":"99","author":"Lenich","year":"2025","journal-title":"Arch Toxicol"},{"issue":"12","key":"10.1016\/j.dmd.2026.100283_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100202","article-title":"Prediction of human hepatic clearance with HepaSH monolayers for low-turnover compounds","volume":"53","author":"Uehara","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2026.100283_bib29","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3390\/metabo14100522","article-title":"Metabolite measurement in index substrate drug interaction studies: a review of the literature and recent new drug application reviews","volume":"14","author":"Yu","year":"2024","journal-title":"Metabolites"},{"key":"10.1016\/j.dmd.2026.100283_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2025.101496","article-title":"Japanese medicinal drug labeling for use in the clinical setting as informed by pharmacogenomic data on cytochrome P450 enzymes obtained from in silico studies","volume":"64","author":"Tanaka","year":"2025","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"10.1016\/j.dmd.2026.100283_bib31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/dmd.109.029710","article-title":"Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques","volume":"38","author":"Uno","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2026.100283_bib32","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1021\/acs.chemrestox.8b00257","article-title":"Cytochrome P450 1A1, 2C9, 2C19, and 3A4 polymorphisms account for interindividual variability of toxicological drug metabolism in cynomolgus macaques","volume":"31","author":"Uno","year":"2018","journal-title":"Chem Res Toxicol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100283_bib33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2131\/jts.38.349","article-title":"CYP3A4 intron 6 C>T polymorphism (CYP3A4\u221722) is associated with reduced CYP3A4 protein level and function in human liver microsomes","volume":"38","author":"Okubo","year":"2013","journal-title":"J Toxicol Sci"},{"key":"10.1016\/j.dmd.2026.100283_bib34","article-title":"Probe drug T-1032 N-oxygenation mediated by cytochrome P450 3A5 in human hepatocytes in vitro and in humanized-liver mice in vivo","volume":"44","author":"Uehara","year":"2022","journal-title":"Drug Metab Pharmacokinet"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T10:14:18Z","timestamp":1779790458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0090955626000528"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100283","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline variations in in vivo cytochrome P450 3A-dependent phenotypes evaluated using concentrations of endogenous or deuterium-labeled cortisol and their 6\u03b2-hydroxylated metabolites in 103 cynomolgus monkeys and 20 humanized-liver mice transplanted with hepatocytes","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100283"}}